AbbVie Forecasts High Single-Digit Growth Through 2030

CFO highlights company's robust portfolio and confident outlook at healthcare conference

Mar. 10, 2026 at 6:10pm

Got story updates? Submit your updates here. ›

At the Leerink Global Healthcare Conference, AbbVie's CFO Scott Reents discussed the company's strong growth prospects, noting they are confident in delivering high single-digit growth through the current decade and into the next. Reents cited AbbVie's derisked portfolio of market-approved assets as the foundation for this projected growth.

Why it matters

AbbVie's ability to maintain high growth over the next 10+ years is crucial for the pharmaceutical giant to continue expanding its market share and delivering value to shareholders. The company's confidence in its pipeline and product portfolio signals stability and momentum in a competitive industry.

The details

Reents stated that AbbVie is guiding for $67 billion in revenue in 2026, building on the strong performance seen in 2025. He emphasized that the company has the necessary portfolio of market-approved, derisked assets in place to drive this high single-digit growth projection through the current decade and into the next. Key growth drivers mentioned include the company's blockbuster immunology drug SKYRIZI.

  • AbbVie reported $67 billion in revenue guidance for 2026.
  • The company is confident in delivering high single-digit growth through the 2020s and into the 2030s.

The players

Scott Reents

Executive VP & CFO of AbbVie Inc.

AbbVie Inc.

A global biopharmaceutical company that develops and markets drugs in various therapeutic areas, including immunology, oncology, neuroscience, eye care, and women's health.

Got photos? Submit your photos here. ›

What they’re saying

“We have the portfolio of assets in place today on market derisked, and we've talked about this a lot, driving high single-digit growth through the decade. We're very confident and continue to be very confident in doing that as well as a clear line of sight to robust growth into the next decade as well.”

— Scott Reents, Executive VP & CFO (Seeking Alpha)

The takeaway

AbbVie's confident outlook and robust product portfolio position the company for continued strong growth in the years ahead, underscoring its ability to navigate the competitive pharmaceutical landscape and deliver value to shareholders.